Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 9/20 | 0.51 |
| ▸ | GSK3B | P49841 | 7/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.45 |
| ▸ | CLK1 | P49759 | 3/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.42 |
| ▸ | NFATC1 | O95644 | 3/20 | 0.42 |
| ▸ | MAP3K14 | Q99558 | 3/20 | 0.42 |
| ▸ | AR | P10275 | 5/20 | 0.40 |
| ▸ | CDK2 | P24941 | 3/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.38 |
| ▸ | CDK9 | P50750 | 2/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4491392 | 0.82 | DYRK1A (0.75) | DYRK1AGSK3BCDK5CDK5R1CLK1 | |
| SCHEMBL19100702 | 0.81 | DYRK1A (0.49) | DYRK1AGSK3BCDK5CDK5R1CLK1 | |
| SCHEMBL19100641 | 0.81 | DYRK1A (0.46) | DYRK1AGSK3BCDK5CDK5R1CLK1 | |
| SCHEMBL30957630 | 0.80 | AR (0.62) | DYRK1AGSK3BCDK5CDK5R1CLK1 | |
| SCHEMBL4487796 | 0.80 | DYRK1A (0.56) | DYRK1AGSK3BCDK5CDK5R1CLK1 | |
| SCHEMBL30957480 | 0.80 | DYRK1A (0.56) | DYRK1AGSK3BCDK5CDK5R1CLK1 | |
| SCHEMBL18662633 | 0.80 | DYRK1A (0.64) | DYRK1AGSK3BCDK5CDK5R1CLK1 | |
| SCHEMBL17542614 | 0.80 | AR (0.62) | DYRK1AGSK3BCDK5CDK5R1CLK1 | |
| SCHEMBL19100699 | 0.80 | CDK5 (0.71) | DYRK1AGSK3BCDK5CDK5R1CLK1 | |
| SCHEMBL17339095 | 0.77 | DYRK1A (0.51) | DYRK1AGSK3BCDK5CDK5R1CLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371415-A1 | AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2021-12-02 | — | — | US | disclosed |
| WO-2020057669-A1 | AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY | 上海轶诺药业有限公司 | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371415-A1 | AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY | JAK1, JAK2, JAK3 | DYRK1A 886/4885GSK3B 702/4885CDK5 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.